Michael S. Leapman, MD
Assistant Professor of Urology; Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center
Research & Publications
Biography
News
Research Summary
Dr. Leapman has been recognized for his research in urologic oncology, with an emphasis in prostate cancer, particularly in the area of risk stratification and clinical outcomes research. His work has been published widely including the Journal of Clinical Oncology, European Urology, and the Journal of Urology. He has written numerous review articles and book chapters, and has delivered research presentations and invited lectures at regional and national meetings.
Coauthors
Research Interests
Urinary Bladder Diseases; Delivery of Health Care; Health Services Research; Kidney Diseases; Prostatic Neoplasms; Ureteral Diseases; Urologic Neoplasms
Selected Publications
- Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer.Leapman MS, Wang R, Park HS, Yu JB, Weinreb JC, Gross CP, Ma X. Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology 2019, 124:98-106.
- Active Surveillance in Younger Men With Prostate Cancer.Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR. Active Surveillance in Younger Men With Prostate Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2017, 35:1898-1904.
- Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes.Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. European Urology 2017, 71:750-759.
- Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PloS One 2017, 12:e0185535.
- Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. The Journal Of Urology 2016, 196:1408-1414.